Jeffrey J Tosoian, Yuping Zhang, Lanbo Xiao, Cassie Xie, Nathan L Samora, Yashar S Niknafs, Zoey Chopra, Javed Siddiqui, Heng Zheng, Grace Herron, Neil Vaishampayan, Hunter S Robinson, Kumaran Arivoli, Bruce J Trock, Ashley E Ross, Todd M Morgan, Ganesh S Palapattu, Simpa S Salami, Lakshmi P Kunju, Scott A Tomlins, Lori J Sokoll, Daniel W Chan, Sudhir Srivastava, Ziding Feng, Martin G Sanda, Yingye Zheng, John T Wei, Arul M Chinnaiyan
IMPORTANCE: Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection of indolent cancers resulting from the poor specificity of PSA for high-grade PCa (ie, grade group [GG] 2 or greater). OBJECTIVE: To develop a multiplex urinary panel for high-grade PCa and validate its external performance relative to current guideline-endorsed biomarkers. DESIGN, SETTING, AND PARTICIPANTS: RNA sequencing analysis of 58 724 genes identified 54 markers of PCa, including 17 markers uniquely overexpressed by high-grade cancers...
April 18, 2024: JAMA Oncology